MR quantitative biomarkers of non-alcoholic fatty liver disease: technical evolutions and future trends.
about
Quantitative Imaging Biomarkers of NAFLDNoninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver diseaseIn vivo breath-hold (1) H MRS simultaneous estimation of liver proton density fat fraction, and T1 and T2 of water and fat, with a multi-TR, multi-TE sequence.MR quantification of total liver fat in patients with impaired glucose tolerance and healthy subjectsDecreases in molecular diffusion, perfusion fraction and perfusion-related diffusion in fibrotic livers: a prospective clinical intravoxel incoherent motion MR imaging studyMultidisciplinary care of obese children and adolescents for one year reduces ectopic fat content in liver and skeletal muscle.Quantitative Three-Dimensional Imaging of Lipid, Protein, and Water Contents via X-Ray Phase-Contrast Tomography.Liver fat content is negatively associated with atherosclerotic carotid plaque in type 2 diabetic patients.Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adultsEvaluation of Nonalcoholic Fatty Liver Disease in C57BL/6J Mice by Using MRI and Histopathologic Analyses.Black blood T1rho MR imaging may diagnose early stage liver fibrosis: a proof-of-principle study with rat biliary duct ligation modelNoninvasive imaging assessment of non-alcoholic fatty liver disease: focus on liver scintigraphy.Chemical exchange saturation transfer (CEST) MR technique for in-vivo liver imaging at 3.0 tesla.Chemical Exchange Saturation Transfer (CEST) MR Technique for Liver Imaging at 3.0 Tesla: an Evaluation of Different Offset Number and an After-Meal and Over-Night-Fast Comparison.
P2860
Q26768664-D25DE165-53F2-45FC-A539-A1053E1715A9Q28082686-A31CDCBA-D490-4805-B13B-BE86A11F2151Q30376231-D4F24321-C374-4140-B75D-9752ADB72C5AQ30976946-5E48ADA2-E5F7-4094-AC68-785850474880Q34400980-F657137F-A466-48D5-A3DB-AF95563C7CEEQ34600947-CC1BB1A9-05CC-4C43-8177-4D67E45AE44EQ35880997-6E46E689-4002-4B3F-BCDD-14D6B5D2BA67Q35966131-0F948BC0-F86B-415A-AEB6-9430ED0DEA85Q36427402-E0A80518-8D3C-4826-A291-B968FED099A8Q36762955-33728FE5-86CB-4532-BF07-2C1D9F1FEB91Q40424699-9A063933-E44B-4DD6-A6D3-C6CB0373493BQ41001675-0D41A016-B212-4458-841D-6D02C3297DDDQ42613401-1DD90C5B-0AA1-42D0-96D6-611940DCC7F4Q47120069-E5D3E6E3-DC3B-420E-8722-02A62A34FD5DQ50244620-A7E80672-E626-4A2B-80AB-5E67D35E4340
P2860
MR quantitative biomarkers of non-alcoholic fatty liver disease: technical evolutions and future trends.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
MR quantitative biomarkers of ...... evolutions and future trends.
@ast
MR quantitative biomarkers of ...... evolutions and future trends.
@en
MR quantitative biomarkers of ...... evolutions and future trends.
@nl
type
label
MR quantitative biomarkers of ...... evolutions and future trends.
@ast
MR quantitative biomarkers of ...... evolutions and future trends.
@en
MR quantitative biomarkers of ...... evolutions and future trends.
@nl
prefLabel
MR quantitative biomarkers of ...... evolutions and future trends.
@ast
MR quantitative biomarkers of ...... evolutions and future trends.
@en
MR quantitative biomarkers of ...... evolutions and future trends.
@nl
P2093
P2860
P1476
MR quantitative biomarkers of ...... evolutions and future trends.
@en
P2093
Chiara Stentarelli
Giovanni Guaraldi
Giulia Besutti
Guido Ligabue
Riccardo Scaglioni
P2860
P304
P356
10.3978/J.ISSN.2223-4292.2013.08.01
P577
2013-08-01T00:00:00Z